CHAMGAP
APPROVEDReviewed and approved by the Chamgap Editorial Team (2026-08-14). The draft was written by AI, the existence of all 2 cited sources was verified at the original page, and the verdict passed blind grading and adversarial audit. Methodology v0.7.
Verdict No. 2492 · Search date 2026-08-14 · Methodology v0.7

Classroom HEPA air cleaners,
does it really help with Reduced asthma symptom-days versus sham units?

30-Second Summary
D
Evidence Grade D · 30 · Safety acceptable
Portable classroom HEPA air cleaners did not significantly reduce asthma symptom-days in a well-controlled school trial.
No air-cleaner-related adverse events were reported in the trial. The device should not replace prescribed inhalers or a clinician-directed asthma action plan.
What the
research shows
The grade is D. In a sham-controlled cluster randomized trial of 236 students across 41 schools, two-week asthma symptom-days averaged 1.6 with HEPA and 1.8 with sham, and the prespecified primary analysis was not significant (IRR 1.47, 95% CI 0.79-2.75). The intervention was tested directly in people but benefit was not established, and the interval remained wide, giving D with 30 points.
What the
ads claim
A HEPA label describes a particle-filtration method; it does not guarantee fewer asthma symptoms. Room-appropriate clean-air delivery, noise, and filter replacement costs should be considered, and filtration remains an adjunct to medication and exposure management.
*

Useful facts when choosing a product

  • Active and sham units were matched in appearance and sound to support masking.
  • The trial was conducted in classrooms attended by students with asthma and does not directly establish effects in homes, adult workplaces, or wildfire-smoke episodes.
  • Verdict 1518 concerns vitamin D for asthma exacerbation prevention, a different intervention; the pivotal PMID and DOI were absent from existing verdicts.
Gap Measurement · Verdict 2492 · D 30
What advertising claims
What independent, higher-quality research supports
△ GAP
01

What the research actually shows

Phipatanakul 2021 used a split-plot factorial design with school-level pest management and independently assigned classroom HEPA filtration. The air-cleaner main effect allocated 118 versus 118 and included all randomized students in the analysis framework, while the primary table observed 105 versus 97. Two-week symptom-days averaged 1.6 versus 1.8; the reported IRR was 1.47 (95% CI 0.79-2.75). Both the paper and NCT02291302 named two-week symptom-days as the prespecified primary outcome, and the registered comparator was sham. Public grants were the principal funding, while Coway supplied the purifiers.

02

Why this is classified as D (30)

This direct trial had long follow-up, complete retention, a sham control, and concordant prospective primary outcome, but the effect was null and the interval was too wide to exclude meaningful benefit. One null confirmatory trial gives D with 30 points.

Counterpoint. The verdict is limited to average symptom-days from portable classroom HEPA units. It does not deny physical particle removal or possible effects in specific high-exposure settings.

Rejudgment record. Cross-check applied — We cross-checked allocation, sham design, completed population, registered primary endpoint, main effect, and grant/in-kind support against the JAMA paper, protocol, and NCT02291302.

Scoring profile behind this grade
EndpointPPatient-reported treatment goal - the symptom is the goal
ReplicationR1Single confirmatory trial
IndependenceI1Mixed funding sources
Effect sizeE0Null
PrecisionC0The confidence interval leaves room for benefit

The scoring table and the verdict agree (D).

Sub-claim grades by effect

This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.

Effect (sub-claim)GradeBasis
Classroom HEPA air cleaners reduce asthma symptom-days versus sham.DThe prespecified primary analysis in 236 students was null and imprecise.

Cross-check — Codex and Claude

This verdict was drafted by Codex through literature review and source-existence checks, cross-checked through blind grading and adversarial audit, and settled by reapplying the methodology boundary rules. Cases with split grades were resolved through rejudgment.
03

Evidence Table

StudyDesignSampleFundingEndpointResultWeight
Study 1School/classroom split-plot factorial cluster-randomized sham-controlled trial97Public grants including NIH and EPA; HEPA units supplied by CowayTwo-week asthma symptom-days measured repeatedly over 10 monthsMean 1.6 versus 1.8 days; IRR 1.47 (95% CI 0.79-2.75), not significantOnly large direct sham-controlled trial
§

Receipt — 2 References

All 2 cited sources were verified for existence at the original page (as of 2026-08-14).

Phipatanakul W, Koutrakis P, Coull BA, et al. Effect of School Integrated Pest Management or Classroom Air Filter Purifiers on Asthma Symptoms in Students With Active Asthma: A Randomized Clinical Trial. JAMA. 2021;326(9):839-850. PMID: 34547084. PMCID: PMC8424475. DOI: 10.1001/jama.2021.11559. NCT02291302.
checked
ClinicalTrials.gov. School Inner-City Asthma Intervention Study (SICAS-2). NCT02291302.
checked
Draft and rewrite: Codex (AI) · Verification: Codex blind grading and adversarial audit · Final adjudication: Claude
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-08-14 · Corrections: none

Cite this verdict

Classroom HEPA air cleaners x asthma symptom-days Evidence Grade D card
[Chamgap] Classroom HEPA air cleaners x asthma symptom-days — Evidence Grade D·30. 2 cited sources checked. Source: https://chamgap.com/en/verdicts/immunity/classroom-hepa-air-cleaner-asthma-symptom-days/ · CC BY 4.0

CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.

!

What this document does and does not do

Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.